| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 586 | 2017 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 186 | 2019 |
| Serum cytokine and chemokine profiles in patients with myasthenia gravis A Uzawa, N Kawaguchi, K Himuro, T Kanai, S Kuwabara Clinical & Experimental Immunology 176 (2), 232-237, 2014 | 80 | 2014 |
| Changes in inflammatory cytokine networks in myasthenia gravis A Uzawa, T Kanai, N Kawaguchi, F Oda, K Himuro, S Kuwabara Scientific reports 6 (1), 25886, 2016 | 58 | 2016 |
| Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study Y Nagane, H Murai, T Imai, D Yamamoto, E Tsuda, N Minami, Y Suzuki, ... BMJ open 7 (2), e013278, 2017 | 53 | 2017 |
| A clinical predictive score for postoperative myasthenic crisis T Kanai, A Uzawa, Y Sato, S Suzuki, N Kawaguchi, K Himuro, F Oda, ... Annals of Neurology 82 (5), 841-849, 2017 | 40 | 2017 |
| Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis A Uzawa, N Kawaguchi, T Kanai, K Himuro, F Oda, S Yoshida, I Yoshino, ... Journal of neurology 262, 1019-1023, 2015 | 39 | 2015 |
| ‘Minimal symptom expression’in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab J Vissing, S Jacob, KP Fujita, F O’Brien, JF Howard Journal of neurology 267 (7), 1991-2001, 2020 | 34 | 2020 |
| Adequate tacrolimus concentration for myasthenia gravis treatment T Kanai, A Uzawa, N Kawaguchi, K Himuro, F Oda, Y Ozawa, S Kuwabara European journal of neurology 24 (2), 270-275, 2017 | 31 | 2017 |
| HLA-DRB1* 14 and DQB1* 05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients T Kanai, A Uzawa, N Kawaguchi, T Sakamaki, Y Yoshiyama, K Himuro, ... Journal of the neurological sciences 363, 116-118, 2016 | 27 | 2016 |
| Serum high mobility group box 1 is upregulated in myasthenia gravis A Uzawa, N Kawaguchi, T Kanai, K Himuro, S Kuwabara Journal of Neurology, Neurosurgery & Psychiatry 86 (6), 695-697, 2015 | 27 | 2015 |
| Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis Y Ozawa, A Uzawa, T Kanai, F Oda, M Yasuda, N Kawaguchi, K Himuro, ... Journal of the Neurological Sciences 402, 12-15, 2019 | 25 | 2019 |
| Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis T Kanai, A Uzawa, N Kawaguchi, F Oda, Y Ozawa, K Himuro, S Kuwabara Journal of the Neurological Sciences 396, 8-11, 2019 | 21 | 2019 |
| Consistent improvement with eculizumab across muscle groups in myasthenia gravis R Mantegazza, FL O'Brien, M Yountz, JF Howard Jr, REGAIN Study Group, ... Annals of clinical and translational neurology 7 (8), 1327-1339, 2020 | 20 | 2020 |
| Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study H Murai, A Uzawa, Y Suzuki, T Imai, H Shiraishi, H Suzuki, M Okumura, ... Journal of the neurological sciences 407, 116419, 2019 | 20 | 2019 |
| Transient global amnesia with a hippocampal lesion followed by transient epileptic amnesia A Sugiyama, M Kobayashi, T Matsunaga, T Kanai, S Kuwabara Seizure 31, 141-143, 2015 | 16 | 2015 |
| Frequency and features of myasthenia gravis developing after thymectomy A Uzawa, T Kanai, F Oda, Y Ozawa, M Yasuda, N Kawaguchi, K Himuro, ... European Journal of Neurology 27 (1), 175-180, 2020 | 13 | 2020 |
| Increased serum peroxiredoxin 5 levels in myasthenia gravis A Uzawa, N Kawaguchi, T Kanai, K Himuro, F Oda, S Kuwabara Journal of Neuroimmunology 287, 16-18, 2015 | 13 | 2015 |
| Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study ZA Siddiqi, RJ Nowak, T Mozaffar, F O'Brien, M Yountz, F Patti, ... Muscle & nerve 64 (6), 662-669, 2021 | 12 | 2021 |
| Long-term outcomes and prognostic factors in generalized myasthenia gravis Y Ozawa, A Uzawa, M Yasuda, Y Kojima, Y Onishi, F Oda, T Kanai, ... Journal of Neurology, 1-8, 2021 | 9 | 2021 |
